Evaluation of zonisamide for the treatment of focal epilepsy: a review of pharmacokinetics, clinical efficacy and adverse effects

References

• Fisher RS, Cross JH, French JA, et al. Operational classification of seizure types by the international league against epilepsy: position paper of the ILAE commission for classification and terminology. Epilepsia. 2017;58(4):522–530.
   Google Scholar
• Singh A, Trevick S. The epidemiology of global epilepsy. Neurol Clin. 2016;34(4):837–847.
   Google Scholar
• Kun Y, Zejun D, Jian Z, et al. Surgical histopathologic findings of 232 Chinese children cases with drug-resistant seizures. Brain Behav. 2020;00: e01565.
   Google Scholar
• Stefanidou M, Das RR, Beiser AS, et al. Incidence of seizures following initial ischemic stroke in a community-based cohort: the framingham heart study. Seizure. 2017;47:105–110.
   Google Scholar
• Ackermann S, Le Roux S, Wilmshurst JM. Epidemiology of children with epilepsy at a tertiary referral centre in South Africa. Seizure. 2019;70:82–89.
   Google Scholar
• Symonds JD, Zuberi SM, Stewart K, et al. Incidence and phenotypes of childhood-onset genetic epilepsies: a prospective population-based national cohort. Brain J Neurol. 2019;142(8):2303–2318.
   Google Scholar
• Schorner A, Weissert R. Patients with epileptic seizures and multiple sclerosis in a multiple sclerosis center in Southern Germany between 2003–2015. Front Neurol. 2019;10:613.
   Google Scholar
• Nevitt SJ, Sudell M, Weston J, et al. Antiepileptic drug monotherapy for epilepsy: a network meta-analysis of individual participant data. Cochrane Database Syst Rev. 2017 15;12:CD011412.
   Google Scholar
• Semah F, Thomas P, Coulbaut S, et al. Early add-on treatment vs alternative monotherapy in patients with partial epilepsy. Epileptic Disord Int Epilepsy J Videotape. 2014 Jun;16(2):165–174.
   Google Scholar
• Xue-Ping W, Hai-Jiao W, Li-Na Z, et al. Risk factors for drug-resistant epilepsy: a systematic review and meta-analysis. Medicine (Baltimore). 2019;98(30):e16402.
   Google Scholar
• Reddy DS, Golub VM. The pharmacological basis of cannabis therapy for epilepsy. J Pharmacol Exp Ther. 2016;357(1):45–55.
   Google Scholar
• Trinka E, Ben-Menachem E, Kowacs PA, et al. Efficacy and safety of eslicarbazepine acetate versus controlled-release carbamazepine monotherapy in newly diagnosed epilepsy: a phase III double-blind, randomized, parallel-group, multicenter study. Epilepsia. 2018;59(2):479–491.
   Google Scholar
• Kanner AM, Ashman E, Gloss D, et al. Practice guideline update summary: efficacy and tolerability of the new antiepileptic drugs I: treatment of new-onset epilepsy: report of the American epilepsy society and the guideline development, dissemination, and implementation subcommittee of the American academy of neurology. Epilepsy Curr. 2018;18(4):260–268.
   Google Scholar
• Schmitz B, Montouris G, Schäuble B, et al. Assessing the unmet treatment need in partial-onset epilepsy: looking beyond seizure control. Epilepsia [Internet]. 2010;51(11):2231–2240.
   Google Scholar
• Fricke-Galindo I, LLerena A, Jung-Cook H, et al. Carbamazepine adverse drug reactions. Expert Rev Clin Pharmacol [Internet]. 2018;11(7):705–718.
   Google Scholar
• Błaszczyk B, Lasoń W, Czuczwar SJ. Antiepileptic drugs and adverse skin reactions: an update. Pharmacol Rep PR. 2015;67(3):426–434.
   Google Scholar
• Chen B, Choi H, Hirsch LJ, et al. Psychiatric and behavioral side effects of antiepileptic drugs in adults with epilepsy. Epilepsy Behav [Internet]. 2017;76:24–31.
   Google Scholar
• Baftiu A, Lima MH, Svendsen K, et al. Safety aspects of antiepileptic drugs-a population-based study of adverse effects relative to changes in utilisation. Eur J Clin Pharmacol. 2019;75(8):1153–1160.
   Google Scholar
• Bialer M, Johannessen SI, Koepp MJ, et al. Progress report on new antiepileptic drugs: a summary of the fourteenth eilat conference on new antiepileptic drugs and devices (EILAT XIV). II. Drugs in more advanced clinical development. Epilepsia. 2018;59(10):1842–1866.
   Google Scholar
• Baulac M. Introduction to zonisamide. Epilepsy Res. 2006;68(Suppl 2):S3–9.
   Google Scholar
• Zonegran 25 mg Hard Capsules - Summary of Product Characteristics (SmPC) - (emc) [Internet]. [cited 2019 Oct 27]. Available from: https://www.medicines.org.uk/emc/product/72/smpc
   Google Scholar
• Reimers A, Ljung H. An evaluation of zonisamide, including its long-term efficacy, for the treatment of focal epilepsy. Expert Opin Pharmacother. 2019;20(8):909–915.
   Google Scholar
• Uto Y. 1, 2-benzisoxazole: a privileged structure with a potential for polypharmacology. Curr Pharm Des. 2016;22(21):3201–3211.
   Google Scholar
• Leppik IE. Zonisamide: chemistry, mechanism of action, and pharmacokinetics. Seizure [Internet]. 2004;13:S5–9.
   Google Scholar
• O’Neil MJ. The merck index - an encyclopedia of chemicals, drugs, and biologicals. 13th ed. Whitehouse Station, NJ: Merck and Co., Inc; 2001. p. 1817.
   Google Scholar
• Biton V. Clinical pharmacology and mechanism of action of zonisamide. Clin Neuropharmacol. 2007;30(4):230–240.
   Google Scholar
• Tsujii S, Ishisaka M, Shimazawa M, et al. Zonisamide suppresses endoplasmic reticulum stress-induced neuronal cell damage in vitro and in vivo. Eur J Pharmacol. 2015;746:301–307.
   Google Scholar
• Leppik IE. Zonisamide. Epilepsia. 1999;40(Suppl 5):S23–29.
   Google Scholar
• Sills G, Brodie M. Pharmacokinetics and drug interactions with zonisamide. Epilepsia. 2007;48(3):435–441.
   Google Scholar
• Mimaki T. Clinical pharmacology and therapeutic drug monitoring of zonisamide. Ther Drug Monit. 1998;20(6):593–597.
   Google Scholar
• Verdier M-C, Bentué-Ferrer D, Tribut O. le groupe Suivi Thérapeutique Pharmacologique de la Société Française de Pharmacologie et de Thérapeutique. [Therapeutic drug monitoring of zonisamide]. Therapie. 2010;65(1):29–34.
   Google Scholar
• Saruwatari J, Ishitsu T, Nakagawa K. Update on the genetic polymorphisms of drug-metabolizing enzymes in antiepileptic drug therapy. Pharm Basel Switz. 2010;3(8):2709–2732.
   Google Scholar
• Ragueneau-Majlessi I, Levy RH, Bergen D, et al. Carbamazepine pharmacokinetics are not affected by zonisamide: in vitro mechanistic study and in vivo clinical study in epileptic patients. Epilepsy Res. 2004;62(1):1–11.
   Google Scholar
• Patsalos PN. Drug interactions with the newer antiepileptic drugs (AEDs)–part 1: pharmacokinetic and pharmacodynamic interactions between AEDs. Clin Pharmacokinet. 2013;52(11):927–966.
   Google Scholar
• Perucca E, Bialer M. The clinical pharmacokinetics of the newer antiepileptic drugs. Focus on Topiramate, Zonisamide and Tiagabine Clin Pharmacokinet. 1996;31(1):29–46.
   Google Scholar
• Wallander KM, Ohman I, Dahlin M. Zonisamide: pharmacokinetics, efficacy, and adverse events in children with epilepsy. Neuropediatrics. 2014;45(6):362–370.
   Google Scholar
• McStay C, Pierce R, Riley C. Complete recovery after acute zonisamide overdose in an adolescent female. Pediatr Emerg Care. 2018;34(2):e30–1.
   Google Scholar
• Okada Y, Seo T, Ishitsu T, et al. Population estimation regarding the effects of cytochrome P450 2C19 and 3A5 polymorphisms on zonisamide clearance. Ther Drug Monit. 2008;30(4):540–543.
   Google Scholar
• Qiu X, Dai Q, Sun F, et al. Population pharmacokinetics of zonisamide after oral administration in healthy Chinese volunteers. Int J Clin Pharmacol Ther. 2016;54(5):362–368.
   Google Scholar
• Hashimoto Y, Odani A, Tanigawara Y, et al. Population analysis of the dose-dependent pharmacokinetics of zonisamide in epileptic patients. Biol Pharm Bull. 1994;17(2):323–326.
   Google Scholar
• Min KL, Ryu JY, Chang MJ. Development and clinical applications of the dried blood spot method for therapeutic drug monitoring of anti-epileptic drugs. Basic Clin Pharmacol Toxicol. 2019;125(3):215–236.
   Google Scholar
• Alsous M, Hamdan I, Saleh M, et al. Predictors of nonadherence in children and adolescents with epilepsy: a multimethod assessment approach. Epilepsy Behav. 2018;85:205–211.
   Google Scholar
• Baulac M, Patten A, Giorgi L. Long-term safety and efficacy of zonisamide versus carbamazepine monotherapy for treatment of partial seizures in adults with newly diagnosed epilepsy: results of a phase III, randomized, double-blind study. Epilepsia. 2014;55(10):1534–1543.
   Google Scholar
• Michelucci R, Pasini E, Riguzzi P, et al. Myoclonus and seizures in progressive myoclonus epilepsies: pharmacology and therapeutic trials. Epileptic Disord Int Epilepsy J Videotape. 2016;18(S2):145–153.
   Google Scholar
• Seki T, Kumagai N, Maezawa M. Effects of zonisamide monotherapy in children with epilepsy. Seizure. 2004;13(Suppl 1):S26–32. discussion S33.
   Google Scholar
• Eun S-H, Kim HD, Eun B-L, et al. Comparative trial of low- and high-dose zonisamide as monotherapy for childhood epilepsy. Seizure. 2011;20(7):558–563.
   Google Scholar
• Miura H. Zonisamide monotherapy with once-daily dosing in children with cryptogenic localization-related epilepsies: clinical effects and pharmacokinetic studies. Seizure. 2004;13(Suppl 1):S17–23. discussion S24-25.
   Google Scholar
• Baulac M, Brodie MJ, Patten A, et al. Efficacy and tolerability of zonisamide versus controlled-release carbamazepine for newly diagnosed partial epilepsy: a phase 3, randomised, double-blind, non-inferiority trial. Lancet Neurol. 2012;11(7):579–588.
   Google Scholar
• Guerrini R, Rosati A, Segieth J, et al. A randomized phase III trial of adjunctive zonisamide in pediatric patients with partial epilepsy. Epilepsia. 2013;54(8):1473–1480.
   Google Scholar
• Guerrini R, Rosati A, Bradshaw K, et al. Adjunctive zonisamide therapy in the long-term treatment of children with partial epilepsy: results of an open-label extension study of a phase III, randomized, double-blind, placebo-controlled trial. Epilepsia. 2014;55(4):568–578.
   Google Scholar
• Badalyan OL, Trepilets VM, Trepilets SV. Clinical experience of using zonisamide in structural focal epilepsy in children with cerebral palsy. Zh Nevrol Psikhiatr Im S S Korsakova. 2018;118(10.Vyp. 2):90–97.
   Google Scholar
• Belousova E. Zonisamid in additional treatment of pediatric partial epilepsy: a review of efficacy and safety in randomized double blind pacebo-controlled III phase study. Zh Nevrol Psikhiatr Im S S Korsakova. 2015;115(5):46–51.
   Google Scholar
• Lee YJ, Kang HC, Seo JH, et al. Efficacy and tolerability of adjunctive therapy with zonisamide in childhood intractable epilepsy. Brain Dev. 2010;32(3):208–212.
   Google Scholar
• Lu Y, Xiao Z, Yu W, et al. Efficacy and safety of adjunctive zonisamide in adult patients with refractory partial-onset epilepsy: a randomized, double-blind, placebo-controlled trial. Clin Drug Investig. 2011;31(4):221–229.
   Google Scholar
• Schmidt D, Jacob R, Loiseau P, et al. Zonisamide for add-on treatment of refractory partial epilepsy: a European double-blind trial. Epilepsy Res. 1993;15(1):67–73.
   Google Scholar
• Faught E, Ayala R, Montouris GG, et al. Zonisamide 922 Trial Group. Randomized controlled trial of zonisamide for the treatment of refractory partial-onset seizures. Neurology. 2001;57(10):1774–1779.
   Google Scholar
• Dupont S, Striano S, Trinka E, et al. Flexible dosing of adjunctive zonisamide in the treatment of adult partial-onset seizures: a non-comparative, open-label study (ZEUS). Acta Neurol Scand. 2010;121(3):141–148.
   Google Scholar
• Heo K, Lee BI, Yi SD, et al. Short-term efficacy and safety of zonisamide as adjunctive treatment for refractory partial seizures: a multicenter open-label single-arm trial in Korean patients. Seizure. 2012;21(3):188–193.
   Google Scholar
• Brodie MJ, Duncan R, Vespignani H, et al. Dose-dependent safety and efficacy of zonisamide: a randomized, double-blind, placebo-controlled study in patients with refractory partial seizures. Epilepsia. 2005;46(1):31–41.
   Google Scholar
• Sackellares JC, Ramsay RE, Wilder BJ, et al. Randomized, controlled clinical trial of zonisamide as adjunctive treatment for refractory partial seizures. Epilepsia. 2004;45(6):610–617.
   Google Scholar
• Cross JH, Auvin S, Patten A, et al. Safety and tolerability of zonisamide in paediatric patients with epilepsy. Eur J Paediatr Neurol EJPN Off J Eur Paediatr Neurol Soc. 2014;18(6):747–758.
   Google Scholar
• Trinka E, Giorgi L, Patten A, et al. Safety and tolerability of zonisamide in elderly patients with epilepsy. Acta Neurol Scand. 2013;128(6):422–428.
   Google Scholar
• Aggarwal M, Kondeti B, McKenna R. Anticonvulsant/antiepileptic carbonic anhydrase inhibitors: a patent review. Expert Opin Ther Pat. 2013;23(6):717–724.
   Google Scholar
• Wroe S. Zonisamide and renal calculi in patients with epilepsy: how big an issue? Curr Med Res Opin. 2007;23(8):1765–1773.
   Google Scholar
• Gadde KM, Franciscy DM, Wagner HR, et al. Zonisamide for weight loss in obese adults: a randomized controlled trial. JAMA. 2003;289(14):1820–1825.
   Google Scholar
• Ioannides-Demos LL, Proietto J, McNeil JJ. Pharmacotherapy for obesity. Drugs. 2005;65(10):1391–1418.
   Google Scholar
• van Dijkman SC, Rauwé WM, Danhof M, et al. Pharmacokinetic interactions and dosing rationale for antiepileptic drugs in adults and children. Br J Clin Pharmacol. 2018;84(1):97–111.
   Google Scholar
• Patsalos PN. Drug interactions with the newer antiepileptic drugs (AEDs)–Part 2: pharmacokinetic and pharmacodynamic interactions between AEDs and drugs used to treat non-epilepsy disorders. Clin Pharmacokinet. 2013;52(12):1045–1061.
   Google Scholar
• Kwan S-Y, Chuang Y-C, Huang C-W, et al. Zonisamide: review of recent clinical evidence for treatment of epilepsy. CNS Neurosci Ther. 2015;21(9):683–691.
   Google Scholar
• Wilfong AA, Willmore LJ. Zonisamide – a review of experience and use in partial seizures. Neuropsychiatr Dis Treat [Internet]. 2006;2(3):269–280.
   Google Scholar
• Drugs@FDA: FDA approved drug products [Internet]. [cited 2019 Sep 15]. Available from: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=077625
   Google Scholar
• Buoli M, Grassi S, Ciappolino V, et al. The use of zonisamide for the treatment of psychiatric disorders: a systematic review. Clin Neuropharmacol. 2017;40(2):85–92.
   Google Scholar
• Matsunaga S, Kishi T, Iwata N. Combination therapy with zonisamide and antiparkinson drugs for Parkinson’s disease: a meta-analysis. J Alzheimers Dis JAD. 2017;56(4):1229–1239.
   Google Scholar
• Eskandari D, Zou D, Karimi M, et al. Zonisamide reduces obstructive sleep apnoea: a randomised placebo-controlled study. Eur Respir J. 2014;44(1):140–149.
   Google Scholar